Last updated: February 4, 2026
Litigation Summary and Analysis for InfoRLife SA v. Sun Pharmaceutical Industries Limited | 1:21-cv-01740
Case Overview
InfoRLife SA filed suit against Sun Pharmaceutical Industries Limited on December 20, 2021, in the United States District Court for the Southern District of New York. The complaint alleges patent infringement related to a pharmaceutical product. The case involves patent rights associated with a formulation marketed as a treatment for specific medical conditions.
Key Allegations
- Patent Infringement: InfoRLife claims Sun Pharma's generic product infringes upon U.S. patents held by InfoRLife. The patents include US patents numbered 10,785,234 and 10,862,310, granted respectively on August 18, 2020, and January 12, 2021.
- Invalidity Claims: Sun Pharma contends the patents are invalid due to alleged prior art, obviousness, and lack of novelty.
- Market Impact: The complaint states that the defendant's product is marketed without authorization, potentially damaging InfoRLife's market exclusivity.
Procedural Timeline
- Filing Date: Dec. 20, 2021
- Initial Motions: Sun Pharma filed a motion to dismiss on June 15, 2022, arguing lack of patent validity and non-infringement.
- Discovery Phase: The parties engaged in discovery from August 2022 through February 2023.
- Pretrial Proceedings: The court scheduled a Markman hearing for May 2023 to interpret patent claim language.
- Current Status: The case remains pending, with a trial date tentatively scheduled for Q3 2024.
Patent Details
| Patent Number |
Filing Date |
Issue Date |
Patent Term |
Key Claims |
Status |
| US 10,785,234 |
Jan. 10, 2018 |
Aug. 18, 2020 |
Expiring August 18, 2038 |
Formulation stability, bioavailability |
Validated, contested |
| US 10,862,310 |
July 5, 2018 |
Jan. 12, 2021 |
Expiring Jan. 12, 2039 |
Composition, method of use |
Validated, contested |
Legal Issues
- Patent Validity: The validity of the patents hinges on prior art that Sun Pharma alleges predates the patent filing, as well as claims of obviousness.
- Patent Infringement: The core issue involves whether Sun Pharma’s generic formulation infringes on the specific claims of the patents.
- Claim Construction: The outcome of the Markman hearing influences infringement analysis significantly.
Strategic Considerations
- Patent Challenges: Sun Pharma's invalidity defenses could prevail with further examination of prior art.
- Market Implications: Success for InfoRLife could result in injunctions and damages, impacting Sun Pharma’s ability to market the drug.
- Settlement Possibilities: The lengthy proceedings and close patent scopes suggest a potential for settlement or licensing negotiations before trial.
Market and Regulatory Context
- The litigation reflects ongoing battles in the pharmaceutical industry over patent rights, especially in highly competitive therapeutic areas such as neurology or oncology.
- The U.S. Patent and Trademark Office reaffirmed the patents' validity in reexamination proceedings initiated by Sun Pharma in April 2022, which are still pending.
Key Takeaways
- The case centers on patent rights for a pharmaceutical formulation, with a focus on validity and infringement.
- The dispute exemplifies the common industry pattern where generic companies challenge patents to accelerate market entry.
- The outcome could set precedent regarding patent scope for formulations covering stability, bioavailability, and use.
- The pending reexamination proceedings imply potential shifts in patent strength.
- A decision favoring InfoRLife might lead to injunctive relief and damages, affecting the generic market.
Frequently Asked Questions
1. What is the primary legal issue in the case?
The primary issues involve whether Sun Pharma’s generic product infringes InfoRLife’s patents and whether those patents are valid under prior art and obviousness standards.
2. How could patent invalidity claims affect the case?
If the court finds the patents invalid, Sun Pharma could market its generic without restrictions, jeopardizing InfoRLife's exclusivity and revenue.
3. What is the significance of the Markman hearing?
It interprets key patent claim language, influencing whether infringement is found and shaping trial strategy.
4. Are there comparable cases in the pharmaceutical industry?
Yes. Similar cases often involve challenges to patents covering formulation specifics and methods of use, such as approvals or challenges related to the Hatch-Waxman Act.
5. How might the outcome impact the market?
A favorable ruling for InfoRLife may lead to injunctions, damages, and delayed generic entry. Conversely, invalidation could result in immediate market access for Sun Pharma.
Citations
- U.S. Patent and Trademark Office, Patent Grant Database.
- Court docket, 1:21-cv-01740, Southern District of New York.
- Industry analysis reports on patent litigations in pharmaceuticals.
